Brinzolamide — Discount Pricing

Other medications in Ophthalmology

• Cyclopentolate
• Cyclosporine Ophthalmic
• Dorzolamide
• Faricimab
• Fluorescein
• Latanoprost
• Latanoprostene Bunod
• Lifitegrast

What Brinzolamide is approved for (FDA label)

Brinzolamide ophthalmic suspension is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Brinzolamide ophthalmic suspension is a carbonic anhydrase inhibitor indicated for in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: April 20, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Brinzolamide (FDA label)

Ophthalmic suspension containing brinzolamide 10 mg/mL (1%). Ophthalmic suspension containing brinzolamide 10 mg/mL (1%)( 3 )

Source: FDA prescribing information (DailyMed). Set ID: fb7229d4-522e-4cb2-b513-9d34f3ded591. SPL document ID: 4fe88efe-d05e-0f99-e063-6294a90a51d3. Label effective date: April 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Brinzolamide (FDA label)

Most common adverse reactions (incidence 5 to 10%) are blurred vision and bitter, sour, or unusual taste ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical studies of brinzolamide ophthalmic suspension, the most frequently reported adverse reactions reported in 5% to 10% of patients were blurred vision and bitter, sour or unusual taste.

Source: FDA prescribing information (DailyMed). Set ID: fb7229d4-522e-4cb2-b513-9d34f3ded591. SPL document ID: 4fe88efe-d05e-0f99-e063-6294a90a51d3. Label effective date: April 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Brinzolamide (FDA label)

Brinzolamide ophthalmic suspension is contraindicated in patients who are hypersensitive to any component of this product. Hypersensitivity to any component of this product ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: fb7229d4-522e-4cb2-b513-9d34f3ded591. SPL document ID: 4fe88efe-d05e-0f99-e063-6294a90a51d3. Label effective date: April 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Brinzolamide (FDA label)

Sulfonamide hypersensitivity reactions ( 5.1 ) Corneal edema may occur in patients with low endothelial cell counts ( 5.2 ) 5.1 Sulfonamide Hypersensitivity Reactions Brinzolamide ophthalmic suspension is a sulfonamide and although administered topically, it is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of brinzolamide ophthalmic suspension. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation. 5.2 Corneal Endothelium Carbonic anhydrase activity has been observed in both the cytoplasm and around the plasma membranes of the corneal endothelium.

Source: FDA prescribing information (DailyMed). Set ID: fb7229d4-522e-4cb2-b513-9d34f3ded591. SPL document ID: 4fe88efe-d05e-0f99-e063-6294a90a51d3. Label effective date: April 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Brinzolamide (FDA label)

There is a potential additive effect of the known systemic effects of carbonic anhydrase inhibition in patients receiving both oral and topical carbonic anhydrase inhibitors ( 7.1 ) Rare instances of acid-base alterations have occurred with high-dose salicylate therapy ( 7.2 ) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and brinzolamide ophthalmic suspension. The concomitant administration of brinzolamide ophthalmic suspension and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Carbonic anhydrase inhibitors may produce acid-base and electrolyte alterations. These alterations were not reported in the clinical trials with brinzolamide. However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of acid-base alterations have occurred with high-dose salicylate therapy.

Source: FDA prescribing information (DailyMed). Set ID: fb7229d4-522e-4cb2-b513-9d34f3ded591. SPL document ID: 4fe88efe-d05e-0f99-e063-6294a90a51d3. Label effective date: April 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.